Caris Life Sciences, Inc. (CAI)
| Market Cap | 4.57B |
| Revenue (ttm) | 907.29M +100.5% |
| Net Income | -411.42M |
| EPS | -1.80 |
| Shares Out | 282.66M |
| PE Ratio | n/a |
| Forward PE | 83.72 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,874,436 |
| Open | 16.80 |
| Previous Close | 19.84 |
| Day's Range | 15.71 - 17.39 |
| 52-Week Range | 15.71 - 42.50 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 29.17 (+80.62%) |
| Earnings Date | May 7, 2026 |
About CAI
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company’s molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecula... [Read more]
Financial Performance
In 2025, Caris Life Sciences's revenue was $812.03 million, an increase of 96.97% compared to the previous year's $412.26 million. Losses were -$537.96 million, 42.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for CAI stock is "Strong Buy." The 12-month stock price target is $29.17, which is an increase of 80.62% from the latest price.
News
Caris Life Sciences submits application to NYSDOH for Caris Assure testing
Caris Life Sciences (CAI) announced that it has submitted an application to the New York State Department of Health Clinical Laboratory Evaluation Program, administered through the Wadsworth Center, s...
Caris Life Sciences price target lowered to $22 from $28 at Baird
Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Caris Life Sciences (CAI) to $22 from $28 and keeps an Outperform rating on the shares. The firm updated
Caris Life Sciences price target lowered to $32 from $38 at BTIG
BTIG analyst Mark Massaro lowered the firm’s price target on Caris Life Sciences (CAI) to $32 from $38 and keeps a Buy rating on the shares. The company’s Q1 results
Caris Life Sciences price target lowered to $30 from $35 at JPMorgan
JPMorgan lowered the firm’s price target on Caris Life Sciences (CAI) to $30 from $35 and keeps an Overweight rating on the shares.
Caris Life Sciences price target lowered to $28 from $35 at Citi
Citi lowered the firm’s price target on Caris Life Sciences (CAI) to $28 from $35 and keeps a Buy rating on the shares.
Caris Life Sciences reports Q1 EPS 0c, consensus (2c)
Reports Q1 revenue $216.2M, consensus $209.67M. “We delivered another strong quarter with record performance for February and March following our January sales re-alignment. This performance underscor...
Caris Life Sciences still sees 2026 revenue $1.0B-$1.02B, consensus $1.01B
16:24 EDT Caris Life Sciences (CAI) still sees 2026 revenue $1.0B-$1.02B, consensus $1.01B
Caris Life Sciences Earnings Call Transcript: Q1 2026
Q1 2026 saw 79% revenue growth to $216M, driven by clinical profiling and new product launches. Gross margin rose to 65%, with positive adjusted EBITDA and free cash flow. Guidance for strong volume and revenue growth is reaffirmed, supported by a robust pipeline and commercial expansion.
Caris Life Sciences’ ChromoSeq receives MolDX approval
Caris Life Sciences (CAI) announced that Caris ChromoSeq has received MolDX approval, a milestone supporting broader clinical access to Caris’ comprehensive whole genome tumor profiling assay for myel...
Caris Life Sciences initiated with a Buy at Jefferies
Jefferies analyst Tycho Peterson initiated coverage of Caris Life Sciences (CAI) with a Buy rating and $28 price target The firm sees “secular tailwinds” in the oncology diagnostics space from
Caris Life Sciences initiated with a Neutral at Piper Sandler
Piper Sandler initiated coverage of Caris Life Sciences (CAI) with a Neutral rating and $21 price target The firm says the company has built a “rare combination” of scientific leadership
Caris Life Sciences price target lowered to $30 from $34 at Evercore ISI
Evercore ISI lowered the firm’s price target on Caris Life Sciences (CAI) to $30 from $34 and keeps an Outperform rating on the shares as part of the firm’s medical
Caris Life Sciences launches Caris ChromoSeq tumor profiling assay
Caris Life Sciences (CAI) announced the launch of Caris ChromoSeq, a Whole Genome Sequencing and Whole Transcriptome assay designed to support the comprehensive clinical genomic evaluation of myeloid ...
Caris Life Sciences initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Caris Life Sciences (CAI) with a Buy rating and $27 price target representing 51% upside. The company can continue to see volume growth within the
Caris Life Sciences announces finalized Achieve 1 Study results
Caris Life Sciences (CAI) announced the finalized Achieve 1 Study results. These results represent a major milestone in Caris’ goal to detect cancer earlier, through the future launch of Caris
Caris Life Sciences announces publication of study on GPSai algorithm
Caris Life Sciences (CAI) published a study in JAMA Network Open, titled “An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins.” This study builds on
Caris Life Sciences introduces new Caris AI Insights
Caris Life Sciences (CAI) announced the addition of a platinum resistance AI signature to the growing portfolio of Caris AI Insight. This new signature is designed to predict early platinum
Caris Life Sciences price target lowered to $22 from $30 at Canaccord
Canaccord analyst Kyle Mikson lowered the firm’s price target on Caris Life Sciences (CAI) to $22 from $30 and keeps a Hold rating on the shares. The firm said their
Caris Life Sciences price target raised to $28 from $26 at Baird
Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Caris Life Sciences (CAI) to $28 from $26 and keeps an Outperform rating on the shares. The firm updated
Caris Life Sciences price target lowered to $34 from $38 at Evercore ISI
Evercore ISI lowered the firm’s price target on Caris Life Sciences (CAI) to $34 from $38 and keeps an Outperform rating on the shares.
Caris Life Sciences price target lowered to $38 from $45 at BTIG
BTIG analyst Mark Massaro lowered the firm’s price target on Caris Life Sciences (CAI) to $38 from $45 due to multiple compression but keeps a Buy rating on the shares.
Caris Life Sciences Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw record revenue and profitability, driven by strong molecular profiling growth, improved ASPs, and expanding clinical volumes. 2026 guidance projects continued double-digit growth, positive cash flow, and major investments in early detection and commercial expansion.
Caris Life Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong financial results and cash position support aggressive investment in technology, commercial expansion, and a robust product pipeline. Early detection and MCED programs are advancing, with new partnerships and market penetration expected to drive growth in 2026 and beyond.
Caris Life Sciences Earnings Call Transcript: Q3 2025
Q3 2025 saw 113% revenue growth, record profitability, and margin expansion, driven by strong clinical profiling and higher ASPs. Guidance for FY25 was raised, with continued investment in early detection, MRD, and data platforms.
Caris Life Sciences Earnings Call Transcript: Q2 2025
Q2 2025 saw 81% revenue growth to $181.4M, driven by clinical and pharma segments, with gross margin up to 62.7%. Positive adjusted EBITDA and free cash flow were achieved, and FY 2025 revenue is guided to $675M–$685M, with strong growth expected in both volumes and ASPs.